Canada · Delayed Price · Currency is CAD Apotex Health Statistics
Total Valuation
Apotex Health has a market cap or net worth of CAD 7.28 billion. The enterprise value is 10.05 billion.
| Market Cap | 7.28B |
| Enterprise Value | 10.05B |
Important Dates
The last earnings date was Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
Apotex Health has 228.50 million shares outstanding.
| Current Share Class | 228.50M |
| Shares Outstanding | 228.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +4.22% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 1.11% |
| Float | 228.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 15.41 |
| PS Ratio | 2.28 |
| PB Ratio | 20.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 58.61 |
| P/OCF Ratio | 27.62 |
| PEG Ratio | 0.54 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.67, with an EV/FCF ratio of 80.85.
| EV / Earnings | n/a |
| EV / Sales | 3.14 |
| EV / EBITDA | 12.67 |
| EV / EBIT | 15.85 |
| EV / FCF | 80.85 |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 8.63.
| Current Ratio | 1.77 |
| Quick Ratio | 0.94 |
| Debt / Equity | 8.63 |
| Debt / EBITDA | 3.81 |
| Debt / FCF | 24.33 |
| Interest Coverage | 2.41 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -11.75% |
| Return on Capital Employed (ROCE) | 18.31% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 532,754 |
| Profits Per Employee | -4,545 |
| Employee Count | 6,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Apotex Health has paid 74.65 million in taxes.
| Income Tax | 74.65M |
| Effective Tax Rate | 157.56% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 35.07 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 35.57 |
| Average Volume (20 Days) | 300,858 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Apotex Health had revenue of CAD 3.20 billion and -27.27 million in losses. Loss per share was -0.16.
| Revenue | 3.20B |
| Gross Profit | 1.62B |
| Operating Income | 633.83M |
| Pretax Income | 47.38M |
| Net Income | -27.27M |
| EBITDA | 761.63M |
| EBIT | 633.83M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 258.76 million in cash and 3.02 billion in debt, with a net cash position of -2.76 billion or -12.10 per share.
| Cash & Cash Equivalents | 258.76M |
| Total Debt | 3.02B |
| Net Cash | -2.76B |
| Net Cash Per Share | -12.10 |
| Equity (Book Value) | 350.19M |
| Book Value Per Share | 1.53 |
| Working Capital | 1.07B |
Cash Flow
In the last 12 months, operating cash flow was 263.66 million and capital expenditures -139.41 million, giving a free cash flow of 124.25 million.
| Operating Cash Flow | 263.66M |
| Capital Expenditures | -139.41M |
| Depreciation & Amortization | 127.80M |
| Net Borrowing | 320.05M |
| Free Cash Flow | 124.25M |
| FCF Per Share | 0.54 |
Margins
Gross margin is 50.69%, with operating and profit margins of 19.83% and -0.85%.
| Gross Margin | 50.69% |
| Operating Margin | 19.83% |
| Pretax Margin | 1.48% |
| Profit Margin | -0.85% |
| EBITDA Margin | 23.83% |
| EBIT Margin | 19.83% |
| FCF Margin | 3.89% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.60%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.60% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 0.60% |
| Earnings Yield | -0.37% |
| FCF Yield | 1.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Apotex Health is 41.34, which is 29.71% higher than the current price. The consensus rating is "Buy".
| Price Target | 41.34 |
| Price Target Difference | 29.71% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 5.21% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Apotex Health has an Altman Z-Score of 1.97 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.97 |
| Piotroski F-Score | 2 |